Evidence map›Paper›PMID 19889971›Full record

ArticleJournal of cell science2009

p53-dependent control of transactivation of the Pen2 promoter by presenilins.

Julie Dunys, Jean Sevalle, Emilie Giaime, Raphaëlle Pardossi-Piquard, Michael P Vitek, Paul Renbaum, Ephrat Levy-Lahad, Yun-wu Zhang, Huaxi Xu, Frédéric Checler and 1 more

Abstract read
In one paragraph

Article in Journal of cell science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Julie DunysInstitut de Pharmacologie Moléculaire et Cellulaire of Centre National de la Recherche Scientifique and Institut de NeuroMédecine Moléculaire, Equipe labellisée Fondation pour la Recherche Médicale, Valbonne, France.
Jean Sevalle
Emilie Giaime
Raphaëlle Pardossi-Piquard
Michael P Vitek
Paul Renbaum
Ephrat Levy-Lahad
Yun-wu Zhang
Huaxi Xu
Frédéric Checler
Cristine Alves da Costa
Fondation pour la Recherche Médicale · FRInstitut de Pharmacologie Moléculaire et Cellulaire · FRSanford Burnham Prebys Medical Discovery Institute · USShaare Zedek Medical Center · ILResearch Triangle Park Foundation · US

Funding

Regulation of Protein Trafficking in NeurodegenerationR01NS046673 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI XU, HUAXI · 2003 to 2018
$5.8M
Transcriptional Regulation of BACE and the Components of the gamma-Secretase CompR01AG030197 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI XU, HUAXI · 2007 to 2011
$1.9M
NIA NIH HHS R01 AG030197NINDS NIH HHS R01 NS046673
6 · The paper itself

Abstract

The senile plaques found in the brains of patients with Alzheimer's disease are mainly due to the accumulation of amyloid beta-peptides (A beta) that are liberated by gamma-secretase, a high molecular weight complex including presenilins, PEN-2, APH-1 and nicastrin. The depletion of each of these proteins disrupts the complex assembly into a functional protease. Here, we describe another level of regulation of this multimeric protease. The depletion of both presenilins drastically reduces Pen2 mRNA levels and its promoter transactivation. Furthermore, overexpression of presenilin-1 lowers Pen2 promoter transactivation, a phenotype abolished by a double mutation known to prevent presenilin-dependent gamma-secretase activity. PEN-2 expression is decreased by depletion of beta-amyloid precursor protein (APP) and increased by the APP intracellular domain (AICD). We show that AICD and APP complement for Pen2 mRNA levels in APP/APLP1-2 knockout fibroblasts. Interestingly, overexpression of presenilin-2 greatly increases Pen2 promoter transactivation. The opposite effect triggered by both presenilins was reminiscent of our previous study, which showed that these two proteins elicit antagonistic effects on p53. Therefore, we examined the contribution of p53 on Pen2 transcription. Pen2 promoter transactivation, and Pen2 mRNA and protein levels were drastically reduced in p53(-/-) fibroblasts. Furthermore, PEN-2 expression could be rescued by p53 complementation in p53- and APP-deficient cells. Interestingly, PEN-2 expression was also reduced in p53-deficient mouse brain. Overall, our study describes a p53-dependent regulation of PEN-2 expression by other members of the gamma-secretase complex, namely presenilins.

Indexed as

Promoter Regions, GeneticTranscriptional ActivationAlzheimer DiseaseAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAnimalsCell LineCells, CulturedFibroblastsHumansMembrane ProteinsMiceMice, KnockoutPresenilin-1Presenilin-2Tumor Suppressor Protein p53Amyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesMembrane ProteinsPresenilin-1Presenilin-2PSENEN protein, humanTumor Suppressor Protein p53

Identifiers

PMID19889971
PMCPMC3188804
OpenAlexW2040541739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.